C4 Therapeutics, Inc.’s Post

From PCR to protein purification, from drug discovery to diagnostics, magnetic beads are a workhorse in the life science industry. Even if you work with magbeads every day, there's always more to learn. Check out this preview of this issue of Magnetosphere, a magazine all about magbeads. Download the full issue here: https://lnkd.in/er7FZSum #magneticbeads #immunodiagnostics #diagnostics

Join this free webinar by the RSC to discover how the Cambridge Structural Database (CSD) with over 1.2M crystal structures can aid in molecular discovery at every stage of your drug design. #moleculardiscovery #drugdesign #CSD #RSC

On October 12, Adam Root, our VP of Protein Sciences, will explain how we are turning drug discovery into a technological pursuit in a webinar hosted by Drug Discovery World and Thermo Fisher Scientific. Learn more 👇  https://lnkd.in/eud_AxJS

We want to hear from you! We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants. Take this short, anonymous survey to share your insights. We’ll compile the responses and share our findings, along with tips to overcome these hurdles, in the Bioprocess Development Forum later this year. The survey takes less than 5 minutes to complete. Let's work together to accelerate antibody downstream process development! https://lnkd.in/erx-yzQR

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐨𝐩 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐟𝐢𝐠𝐮𝐫𝐞𝐬 𝐚𝐭 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟒! 🌟 Day One's Track 2 will dive into 'Identification & Validation - Targeted Protein Degradation' featuring perspectives from Greg Hollingworth, Sanne Schr�der Glad, Nils Jakob Vest Hansen, Diana Zindel, Xiang Yi and Takhar Kasumov! 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫: ✔️ Targeted Protein Degradation And Target Validation ✔️ Induced Proximity and Protein Degradation in Drug Discovery ✔️ Novel Strategy to Induce the Degradation of a Target Protein ✔️ Assay Technology Development & Tools ▶️ See what's planned: https://hubs.la/Q02s4DJQ0 #OGDiscovery #DiscoveryEU24

HJB's material generation platform can produce grams of high-quality proteins in just 7 weeks from receiving the DNA sequence of target genes using stable pools generated from the same expression system used for production cell line development. If a molecular candidate is selected for CMC development, utilizing stable pools for material generation could reduce the timeline from DNA to the clinic by at least 4 weeks. Additionally, materials generated using stable pools are more representative of future clinical materials.

It’s frustrating for your research that a wealth of public experimental data exists, without standardization and meaning. Check out our webinar to learn how to overcome this by leveraging the synergy between QIAGEN Biomedical Knowledge Base #BKB and QIAGEN OmicSoft Lands to fuel your drug discovery programs. #drugdiscovery #bioinformatics ➡️ https://lnkd.in/efYAqghX

Are molecular glues the key to undruggable targets?   In case you missed it, Dr Benedict CS Cross spoke with Labiotech.eu about the growing interest in the field of molecular glues and the potential for this new modality to open up immense new possibilities in degrader drug development. Read the full article here: https://rb.gy/pnzjdu   #MolecularGlues #DrugDiscovery #DrugDevelopment

Are false results and poor sensitivity hampering your immunoassay experiments? Discover how Codetta Bio's innovative approach is changing the game. Codetta Bio's "noise cancelling technology" tackles non-specific molecular interactions head-on, eliminating the cross talk that plagues traditional assays. As plex increases, so does the need for accuracy and reliability. With Codetta Bio, you can finally achieve both. Watch the video to learn more. https://hubs.ly/Q02ypVFc0

The high sensitivity of ELISpot immunoassay technology can answer many complex questions in the journey to making scientific breakthroughs. Find out how ELISpot immunoassays work and how they can be applied: https://lnkd.in/dbvBjvgY #immunoassays #IVD #ELISpot